Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: An analysis of California public family planning administrative claims data, 2007-2010

American Journal of Public Health

Volumn 102, Issue 5, 2012, Pages 833-835

  Bauer, Heidi M ^a   Wright, Glenn ^a   Chow, Joan ^a  

^a CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGE; ARTICLE; CHILD; CONDYLOMA ACUMINATUM; FEMALE; HUMAN; INSURANCE; MALE; STATISTICS; UNITED STATES;

ADOLESCENT; ADULT; AGE FACTORS; CALIFORNIA; CHILD; CONDYLOMATA ACUMINATA; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; MALE; PAPILLOMAVIRUS VACCINES; YOUNG ADULT;

EID: 84861947648     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2011.300465     Document Type: Article

References (15)

1. Ault KA. Epidemiology and natural history of human papillomavirus infections in the female genital tract. Infect Dis Obstet Gynecol. 2006;2006(Suppl):1-5.
2. Dinh TH, Sternberg M, Dunne EF, Markowitz LE. Genital warts among 18- to 59-year-olds in the United States, national health and nutrition examination survey, 1999-2004. Sex Transm Dis. 2008;35(4): 357-360. (Pubitemid 351440776)
3. Barr E, Tamms G. Quadrivalent human papillomavirus vaccine. Clin Infect Dis. 2007;45(5):609-617. (Pubitemid 47328643)
4. Villa LL. Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine. Int J Infect Dis. 2007;11(Suppl 2): S17-S25. (Pubitemid 350298917)
5. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-2):1-24.
6. Centers for Disease Control and Prevention. Recommendations on the use of quadrivalent human papillomavirus vaccine in males - Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011;60(50):1705-1708.
7. Centers for Disease Control and Prevention. National and state vaccination coverage among adolescents aged 13-17 years-United States, 2010. MMWR Morb Mortal Wkly Rep. 2011;60(33):1117-1123.
8. Centers for Disease Control and Prevention. Adult vaccination coverage-United States, 2010. MMWR Morb Mortal Wkly Rep. 2012;61(4):66-72.
9. Chang Y, Brewer NT, Rinas AC, Schmitt K, Smith JS. Evaluating the impact of human papillomavirus vaccines. Vaccine. 2009;27(32):4355-4362.
10. Markowitz LE, Hariri S, Unger ER, Saraiya M, Datta SD, Dunne EF. Post-licensure monitoring of HPV vaccine in the United States. Vaccine. 2010;28(30):4731-4737.
11. Arima Y, Winer RL, Feng Q, et al. Development of genital warts after incident detection of human papillomavirus infection in young men. J Infect Dis. 2010;202(8):1181-1184.
12. Fairley CK, Donovan B. What can surveillance of genital warts tell us? Sex Health. 2010;7(3):325-327.
13. Donovan B, Franklin N, Guy R, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis. 2011;11(1):39-44.
14. Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw CS. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect. 2009;85(7):499-502.
15. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2009. Atlanta: U.S. Department of Health and Human Services; 2010.